Section Arrow
ORKA.NASDAQ
- Oruka Therapeutics Inc
Quotes are at least 15-min delayed:2026/08/05 00:23 EDT
Regular Hours
Last
 98.13
+3.34 (+3.52%)
Day High 
98.72 
Prev. Close
94.79 
1-M High
99 
Volume 
621.26K 
Bid
88
Ask
100
Day Low
94.24 
Open
96.02 
1-M Low
80.72 
Market Cap 
5.72B 
Currency 美元 
P/E -- 
%Yield 67.21 
10-SMA 92.88 
20-SMA 89.95 
50-SMA 78.64 
52-W High 99 
52-W Low 12.84 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.93/-2.56
Enterprise Value
5.72B
Balance Sheet
Book Value Per Share
8.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.3842+0.1041+37.17%-- 
VTGNVistagen Therapeutics, Inc.0.3+0.055+22.45%-- 
RXRXRecursion Pharmaceuticals3.31+0.13+4.09%-- 
IBRXImmunityBio6.95-0.2-2.80%-- 
GOSSGossamer Bio0.1815+0.0079+4.55%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and otherconditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.